1 / 30

The Hepatic Barracuda Hepatitis B

The Hepatic Barracuda Hepatitis B. By William E. Stevens. History of Hepatitis B. 1883 15% receiving small pox vaccination in Germany develop jaundice 1941 > 50,000 U.S. soldiers develop jaundice after yellow fever vaccination

sisk
Télécharger la présentation

The Hepatic Barracuda Hepatitis B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Hepatic BarracudaHepatitis B By William E. Stevens

  2. History of Hepatitis B • 1883 15% receiving small pox vaccination in Germany develop jaundice • 1941 > 50,000 U.S. soldiers develop jaundice after yellow fever vaccination • 1947 “serum hepatitis” is designated Hepatitis B • 1963 Hepatitis B Surface Antigen identified • 1988 Pregnant mothers screened for HBV S Ag • 1991 Universal vaccination for children

  3. The Hepatitis B Virus • Family: Hepadnaviridae • 60% shared homology with human, duck, squirrel, and woodchuck hepatitis viruses • Genome: 3.2 Kb partially double stranded, circular DNA • Structure: • Envelope: Surface Ag, L and M proteins • Nucleocapsid core: Core Ag, DNA, and DNA polymerase

  4. The Hepatitis B Genome • Four partially overlapping open reading frames: • Envelope (Pre S/S) • Large, Middle, and Surface antigens • Core (Precore/core) • Core and E antigens • Polymerase • DNA polymerase with reverse transcriptase activity • X protein • Transactivation protein; ?hepatocarcinogenesis

  5. HBV Replication • L protein binds to hepatocyte membrane • Virus enters by direct fusion of envelope with cell membrane • Viral uncoating in cytoplasm • Nucleocapsid transported to nucleus • Host RNA polymerase transcribes viral DNA into mRNA and genomic RNA • RNA’s transported to cytoplasm for translation • Viral DNA polymerase / reverse transcriptase activity: genomic RNA  Neg DNA  Pos DNA • Virus assembly in Golgi apparatus • Exits hepatocyte by vesicular transport

  6. Hepatitis B Epidemiology • Worldwide • 2 billion have HBV markers (25%) • 400 million have chronic infection (5%) • Tenth leading cause of death in the world (1 million deaths annually) • U.S. • 1.25 million have chronic hepatitis • 50% are first generation Asian immigrants • 200,000 acute infections per year • Number declining since 1985 • 250 deaths / year from fulminant HBV • 4000 deaths / year from chronic HBV • 800 deaths / year from HBV related hepatoma

  7. Hepatitis B EpidemiologyPopulations at Risk Group % HBV S Ag+ • Asian immigrants 10-15% • Native Alaskans 6.4% • Homosexuals 6% • HIV+ 10% • IVDA 7% • Black > White • Men > Women • Peak incidence 20-29 years old

  8. Hepatitis B Transmission • HBV is found in blood and all body fluids except stool • Perinatal transmission • Primary route of infection outside of U.S. • Occurs at or after delivery • 70-90% transmission rate from HBV E Ag + mother to baby • Additional 60% children not infected at birth acquire infection by age 5 • Percutaneous / Sexual transmission • Primary route of transmission in U.S. (80%) • Sexual contact accounts for 50% cases • Percutaneous route accounts for 20% cases • IVDA, health care workers, tattoos, acupuncture, transfusions, hemodialysis, residence in institutions • Unknown causes 30%..... • HBV remains viable in environment for ~7 days

  9. Hepatitis BPathogenesis • Liver injury occurs from host immunologic response • Many chronic carriers with active viral replication have normal ALT • Fulminant HBV occurs due to hyper-vigorous immune response • Cytotoxic T-lymphocytes destroy infected hepatocytes • TNF and gamma-interferon activate non-antigenic clearance pathways

  10. Hepatitis B Variant Viruses • Precore / Core mutants • Point mutation in core promoter region • HBV E Ag negative • Increased likelihood for fulminant hepatitis • E Ag functions as “immune deflector” • More common in Mediterranean region (30%) than U.S. (10%) • Surface gene mutants • Occurs in neonates and transplant patients given HBIG • S Ag pos and S Ab pos • Polymerase gene mutants • Selected for by exposure to nucleoside analogues • HBV Surface Ag negative HBV infection • Rare transmission HBV from S Ag neg Core Ab pos individuals • HBV DNA rarely found in persons lacking all markers • HBV DNA often found in Hepatoma patients that lack S Ag • ? Mutation impairing expression of S Ag

  11. Natural History of Acute Hepatitis B • 3-5% in U.S. have HBV markers • >50% anicteric (subclinical) illness • <1% fulminant hepatitis • 90% have spontaneous resolution < 6 months • Incubation is 60-180 days • S Ag occurs 1-12 weeks after exposure • Core IgM and clinical hepatitis occurs 4 weeks after appearance of S Ag • E Ag indicates period of infectivity • S Ab indicates resolving infection • Rare “window period” between loss of S Ag and before S Ab appears; Core IgM will be positive

  12. Natural History of Chronic Hepatitis B • Persistent S Ag, E Ag, DNA > 6 months • Risk of chronicity is dependent on host age and immune status • Perinatal infection 90% • Childhood infection < age 6 30% • Acute adult infection 5% • HIV coinfection 30%

  13. Phases of Chronic Hepatitis B • Immune Tolerant Phase • S Ag +, E Ag +, DNA +, ALT normal • E Ag rarely clears with ALT fluctuations • Low risk for cirrhosis • Nonreplicative (low replicative) Phase (Integrated Phase) • S Ag+, E Ag--, DNA--, ALT usually normal • Prognosis is good: cirrhotic complications occur in 0.5/1000 patient years • ALT fluctuates in 20%; 50% have low detectable DNA levels • Some will progress to cirrhosis; 97% 5 year survival • Immune Clearance Phase • S Ag +, E Ag+, DNA +, ALT > 2 x normal • Chronic Active Hepatitis • 20% cirrhosis in 5 years (2-4% per year); 72% 5 year survival • 400 times risk of hepatoma • 10% per year spontaneously convert E Ag pos to neg • 1% per year spontaneously loose S Ag

  14. Hepatitis BExtrahepatic Manifestations • Arthralgias and rash 25% • Serum sickness-like syndrome, angioneurotic edema • Polyarteritis nodosa, systemic vasculitis • Mononeuritis, polyneuropathy • Membranoproliferative glomerulonephritis • Arthritis • Raynauds phenomena • Type II mixed essential cryroglobulinemia • Guillian Barre Syndrome • Pancreatitis • Pericarditis

  15. Hepatitis BCoinfection • HIV • 10% with HIV are S Ag+; 80% have HBV markers • Higher viral replication, lower ALT, less inflammation but more fibrosis on biopsy • Progression to cirrhosis is more rapid • Hepatitis C • Lower HBV replication • Increased rate of loss of S Ag • HCV predominates; more progressive liver disease • Hepatitis D • More common in Mediterranean region; uncommon in U.S. • Coinfection or superinfection • 34% fulminant hepatitis; 90% chronic hepatitis • 15% cirrhosis in 1 year

  16. Hepatitis B Prevention • Behavior modification • Eliminate high risk behavior; use condoms • Acute infection has declined for 20 years • Screen pregnant mothers • HBIG and HBV vaccination at birth prevents 95% of perinatal infections • HBV Vaccination • Perinatal exposure • Persons with sexual, mucosal, percutaneous exposures • Persons with HCV or IV drug abuse • Homosexuals • Health care workers • Hemodialysis patients • Universal vaccination for children • Hepatitis B Immune Globulin • Perinatal exposure • Needle stick exposure • Persons with recent sexual, mucosal, percutaneous exposures

  17. Hepatitis BTreatment • Who to treat • Chronic active hepatitis > 6 months duration • S Ag+, E Ag +/-, DNA+, ALT > 2 x normal • Active hepatitis, advanced fibrosis on biopsy • Goal of treatment • Stop viral replication: HBV DNA becomes Neg • Convert E Ag+ to E Ag--; E Ab becomes pos • Improve histology, prevent progression to cirrhosis • Prevent hepatoma • With successful treatment 1-2% per year will loose S Ag

  18. Hepatitis B TreatmentAlpha-interferon 2b • 5 mu sq qd for 4-6 months • 35% response rate: E Ag seroconversion; 10% loose S Ag • Hepatitis flare is common during treatment • Favorable pretreatment variables: • Low HBV DNA levels < 200 pg/ml • High ALT > 100 • Active hepatitis on biopsy • Shorter duration of infection • Others: female, HIV neg

  19. Hepatitis B TreatmentAlpha-Interferon 2b • Pros • Short, finite period of treatment • Effective viral response persists in 90% • After 8 year f/u: hepatoma risk reduced from 12% to 1.5%; survival improved to 98% vs. 57% • No resistant mutants • Cons • Expensive: $ 2000 per month • Side effects; 35% require dose reduction • May cause cirrhosis to decompensate: CONTRAINDICATED • Less effective with E Ag mutants • Lower sustained response rate: 25% • Higher relapse rate: 50% • Requires 12 month treatment

  20. Hepatitis B TreatmentPEG Interferon Alpha 2a • 180 ug sq q week for 48 weeks • 35% became E Ag negative (c/w 25% with standard interferon) • 32% DNA negative • 41% normal ALT • No benefit with addition of lamivudine • Except lower incidence YMDD mutants • Effective with E Ag neg mutants • One year PEG compared to lamivudine treatment: • 20% receiving PEG were DNA Neg 6 months after treatment • 4% became S Ag neg; 59% normal ALT; 81% improved histology • 7 % given lamivudine were DNA Neg after 6 month f/u • 0% were S Ag neg

  21. Hepatitis B TreatmentNucleoside Analogues • Inhibit HBV DNA polymerase / reverse transcriptase • Lamivudine (Epivir) 100 mg po qd • Adefovir (Hepsera) 10 mg po qd • Entecavir (Baraclude) 0.5 mg - 1 mg po qd • Others • Famciclovir ?benefit in combination with lamivudine • Emtricitabine efficacy similar to lamivudine • Tenofovir similar to adefovir, less nephrotoxicity, ideal if HIV+ • Clevudine pyrimadine analogue in phase 1-2 trials

  22. Lamivudine • Competes with dCTP • Normalizes LFT’s, inhibits viral replication, and improves histology • Prolonged use leads to viral resistance • 15-30% per year; 70% at 4 years • YMDD mutants replicate less efficiently • Safe in pregnancy • 0/38 babies developed perinatal HBV • Cost: $230 per month • E Ag seroconvervison occurs in 17% at one year; 50% at 5 years • More effective if ALT higher: 2% response if ALT normal vs. 42% if ALT 5x • Stop treatment 3-6 months after loss of E Ag • 20-40% will relapse • Effective in E Ag negative mutants • 70% are DNA neg at one year; 40% at 3 years • 90% relapse if stopped < 1 year • Delays progression of cirrhosis and reduces risk of Hepatoma • After 3 years: risk of cirrhosis progression reduced from 20% to 10% • Hepatoma risk reduced from 7.4% to 3.9% • No benefit when combined with interferon

  23. Adefovir • Prodrug for AMP analogue • Efficacy seems similar to lamivudine after 1 year • 12% E Ag serosonversion; 43% at 3 years • DNA neg 51%, ALT normal 72%, improved histology 64% • Viral resistance is uncommon: 0% at 1 year, 2.5% at 2 years • Effective in Lamivudine resistance • Effective in E Ag mutants • Cost $500-600 per month • Nephrotoxicity occurs in 2.5% after 1 year • No benefit when combined with lamivudine

  24. Entecavir • Deoxyguanosine analog • In vitro seems more potent than lamivudine, adefovir • O.5 mg/d for nucleoside naïve patients; 1 mg/d for lamivudine resistance • 6% with lamivudine resistance develop resistance to entecavir • Cost: more • Compared to one year treatment with lamivudine: E L • More improved histology: 72% vs 62% • DNA negative: 69% vs 38% • ALT normal: 78% vs 70% • E Ag seroconversion: 21% vs. 18%

  25. Hepatitis B TreatmentAlgorithm

  26. Hepatitis BFollow Up • S Ag +, E Ag -, DNA – • Follow LFT’s every 6-12 months • S Ag +, E Ag +, DNA + • Liver biopsy, stage hepatitis • Treat • Follow LFT’s every 3-6 months • Hepatoma Surveillance • High risk group • Men, age >45, cirrhosis, E Ag +, DNA +, high ALT, ETOH+, HCV +, tobacco+, aflatoxin exposure, family history HCC • AFP every 6 months + US every 6 -12 months • Low risk group: check AFP annually • Surveillance findings • Hepatomas are smaller and more resectable • One study shows improved 1 year survival • Cost of surveillance is $10-15,000 per year of life saved

More Related